During the last session, Moderna Inc (NASDAQ:MRNA)’s traded shares were 11.31 million, with the beta value of the company hitting 2.21. At the end of the trading day, the stock’s price was $34.30, reflecting an intraday loss of -2.58% or -$0.91. The 52-week high for the MRNA share is $170.47, that puts it down -397.0 from that peak though still a striking 14.72% gain since the share price plummeted to a 52-week low of $29.25. The company’s market capitalization is $13.23B, and the average trade volume was 11.32 million shares over the past three months.
Moderna Inc (MRNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.81. MRNA has a Sell rating from 2 analyst(s) out of 17 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 12 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -3.14.
Moderna Inc (NASDAQ:MRNA) trade information
Moderna Inc (MRNA) registered a -2.58% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.58% in intraday trading to $34.30, hitting a weekly high. The stock’s 5-day price performance is 10.32%, and it has moved by 0.38% in 30 days. Based on these gigs, the overall price performance for the year is -64.27%.
The consensus price target of analysts on Wall Street is $58, which implies an increase of 40.86% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $45 and $238 respectively. As a result, MRNA is trading at a discount of -593.88% off the target high and -31.2% off the low.
Moderna Inc (MRNA) estimates and forecasts
In the rating firms’ projections, revenue will decrease -33.92% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 134.46M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 121.45M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 167M and 241M respectively. In this case, analysts expect current quarter sales to shrink by -19.48% and then drop by -49.61% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -42.94%. While earnings are projected to return -8.01% in 2025, the next five years will return 14.65% per annum.
MRNA Dividends
Moderna Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 39.56 million shares, is of VANGUARD GROUP INC’s that is approximately 10.3568% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.7 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Moderna Inc (MRNA) shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 11.0 shares. This amounts to just over 2.85 percent of the company’s overall shares, with a $377.22 million market value. The same data shows that the other fund manager holds slightly less at 9.17, or about 2.38% of the stock, which is worth about $314.37 million.
